Uwe Gerstenmaier
Overview
Explore the profile of Uwe Gerstenmaier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):37.
PMID: 39820556
Background: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the...
2.
Gaidzik V, Mayer-Steinacker R, Wittau M, Schultheiss M, V Baer A, Oehl-Huber K, et al.
Sarcoma
. 2024 Oct;
2024:5036102.
PMID: 39411551
Desmoplastic small round blue cell tumor (DSRCT) is a highly aggressive fatal sarcoma without evidence-based therapeutic guidelines. We present here seven patients with DSRCT including immunohistochemistry combined with fluorescence in...
3.
Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, et al.
Eur J Cancer
. 2024 Sep;
211:114306.
PMID: 39293347
Introduction: Whole Exome Sequencing (WES) has emerged as an efficient tool in clinical cancer diagnostics to broaden the scope from panel-based diagnostics to screening of all genes and enabling robust...
4.
Kumbrink J, Demes M, Jeroch J, Brauninger A, Hartung K, Gerstenmaier U, et al.
Pathol Oncol Res
. 2024 Apr;
30:1611590.
PMID: 38605929
Lung cancer is a paradigm for a genetically driven tumor. A variety of drugs were developed targeting specific biomarkers requiring testing for tumor genetic alterations in relevant biomarkers. Different next-generation...
5.
Frobel J, Bozic T, Lenz M, Uciechowski P, Han Y, Herwartz R, et al.
Clin Chem
. 2017 Nov;
64(3):566-575.
PMID: 29118064
Background: White blood cell counts are routinely measured with automated hematology analyzers, by flow cytometry, or by manual counting. Here, we introduce an alternative approach based on DNA methylation (DNAm)...
6.
Lennerz J, Weissinger S, Gerstenmaier U, Marienfeld R, Moller P
Br J Haematol
. 2016 Jun;
179(1):158-160.
PMID: 27301865
No abstract available.
7.
Eipel M, Mayer F, Arent T, Ferreira M, Birkhofer C, Gerstenmaier U, et al.
Aging (Albany NY)
. 2016 Jun;
8(5):1034-48.
PMID: 27249102
Aging is reflected by highly reproducible DNA methylation (DNAm) changes that open new perspectives for estimation of chronological age in legal medicine. DNA can be harvested non-invasively from cells at...
8.
Weidner C, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, et al.
Oncotarget
. 2016 Feb;
7(10):10765-72.
PMID: 26909595
Dyskeratosis congenita (DKC) is associated with impaired telomere maintenance and with clinical features of premature aging. In this study, we analysed global DNA methylation (DNAm) profiles of DKC patients. Age-associated...